This analysis examines the historical and forecast performance for Shire in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs
Features and benefits
- Gain insight into Shire’s strategic outlook across the next 6 years
- Analyze company sales forecasts by product, therapy area, lifecycle stage, geography, molecule type and source
Highlights
Shire exhibited rapid revenue growth over 2005–11, despite a dip in sales over 2008–09 caused by generic erosion to Adderall XR. Shire’s impressive performance has been driven not only by its effective lifecycle management strategy, but also by strong uptake of its Human Genetic Therapies portfolio.
During the forecast period, Shire is expected to see a slowdown in sales growth. This is largely attributable to the absence of new product launches in the near future, given that its R&D pipeline is largely based on early-stage products.
Your key questions answered
- Benchmark Shire’s performance against key rivals in the prescription pharmaceutical sector
- Assess how successful Shire will be in diversifying its business focus and reducing its reliance on the US ADHD market
- See how Shire has developed a portfolio of products indicated for highly symptomatic diseases in an effort to build sustainable growth
Price : Single User License: US$ 5700 Price : Corporate User License: US$ 14250
Table of Contents
SCOPE OF SHIRE ANALYSIS
PharmaVitae Explorer database
Analysis structure
Strategic Insight
Company Overview
Operating Performance Analysis
EXECUTIVE SUMMARY
Key findings
Shire prescription pharmaceutical sales outlook
Shire financial outlook
SWOT analysis
Weaknesses
Opportunities
Threats
STRATEGIC INSIGHT
Key findings
Launch/core/expiry analysis
Strategic insight
Despite a declining focus in CNS, this therapy area will continue to generate the majority of sales out to 2017
Niche disorders to be Shire’s other key area of sales growth
Generic competition in CNS market justifies switch in focus to niche disorders
CORPORATE STRUCTURE
Key findings
Background
Corporate structure
Human Genetic Therapies
Specialty Pharmaceuticals
Regenerative Medicine
M&A history
M&A strategy
OPERATING PERFORMANCE
Key findings
Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2005–11
Operating costs and profit analysis
Operating costs and profit analysis, 2005–11
Operating cost ratio and profit margin analysis, 2005–11
Operating cost ratio and profit margin analysis, 2011–17
Operating costs and profit analysis, 2011–17
APPENDIX
References
Exchange rates
List of Tables
Table: Datamonitor’s established pharmaceutical company coverage, 2012
Table: Shire – key product overview ($m), 2011–17
Table: Shire’s financial performance ($m), 2011–17
Table: Shire’s launch, core, and expiry portfolio overview ($m), 2011–17
Table: The Gaucher disease market, 2012
Table: Shire’s key merger and acquisition deals, 1995-12
Table: Total Shire sales by business unit ($m), 2005–11
Table: Shire’s operating revenue/cost analysis ($m), 2005–11
Table: Shire’s operating cost ratio analysis (percentage of total revenues), 2005–11
Table: Shire’s operating cost ratio analysis (percentage of total revenues), 2011–17
Table: Shire’s operating revenue/cost analysis ($m), 2011–17
Table: Exchange rates, 2012
List of Figures
Figure: The PharmaVitae Explorer
Figure: Shire’s prescription pharmaceutical performance, sales ($m) and growth rate (%), 2005–17
Figure: Shire’s financial performance ($m), 2005–17
Figure: Shire’s launch/core/expiry configuration ($m), 2011–17
Figure: Shire’s prescription pharmaceutical sales, by therapy area ($m), 2003–17
Figure: Forecast sales of the Gaucher disease drug market ($m), 2011–17
Figure: Shire’s corporate structure
Figure: Shire’s operating revenue/cost analysis ($m), 2005–17
Contact sales@reportsandreports.com for further details.
